Quantcast

Latest Drug Development Stories

2014-09-19 23:08:36

SNBL Clinical Pharmacology Center, Inc. (SNBL CPC), a 96-bed clinical pharmacology research unit specializing in complex early-phase trials, announced today the successful completion of a validation study of the NeuroCart. The study validated the NeuroCart as an effective tool for detection of benzodiazepine-evoked pharmacodynamic CNS effects. Baltimore, MD (PRWEB) September 19, 2014 SNBL Clinical Pharmacology Center, Inc. (SNBL CPC), a 96-bed clinical pharmacology research unit...

2014-09-19 08:25:37

--Use of Crowdsourced Clinical Trial Protocols and Telemonitoring for Remote Patient Data Collection Is Potential Game-Changer for Orphan Diseases NEW YORK, Sept. 19, 2014 /PRNewswire/ -- Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it is applying its expertise in crowdsourcing and digital telemonitoring technology to conduct a clinical trial of Auven Therapeutics' Kiacta(TM)( )in...

2014-09-17 12:27:05

New multi-year grant furthers non-profit organization's work to accelerate the drug development process TUCSON, Ariz., Sept. 17, 2014 /PRNewswire-USNewswire/ -- The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has awarded the organization $2.1 million in first year funding of a five-year grant with the potential of $10.5 million over the five years. This is the second five-year grant that C-Path has received from the FDA under the...

2014-09-16 23:15:45

Seattle’s own Cancer Research And Biostatistics (CRAB), and Translational Drug Development (TD2) in Scottsdale, would like to jointly announce CRAB’s assumption of responsibility for the PCRT, a world-renowned consortium comprised of a team of pancreatic cancer experts committed to improve treatment outcomes for patients with this deadly cancer. Seattle, WA (PRWEB) September 16, 2014 Seattle’s own Cancer Research And Biostatistics (CRAB), and Translational Drug Development (TD2) in...

2014-09-16 23:03:11

Topical research report “Pediatric Drug Development - Regulatory Challenges and Commercial Opportunities” worked out by CBR Pharma Insights is now available at MarketPublishers.com. London, UK (PRWEB) September 16, 2014 Since the adoption of pediatric legislation, the number of paediatric clinical trials has risen considerably in line with increased investment in R&D for pediatric drugs. In the USA, over 350 product labels include novel paediatric information and more than 130...

2014-09-16 12:30:26

BOSTON, September 16, 2014 /PRNewswire/ -- Russia's pharmaceutical market has been growing faster over recent years. The Pharma 2020 Strategy provides incentives for local producers to develop original and generic drugs for both domestic and foreign markets. These trends, however, were affected by recent developments connected with the political situation and the following political and economic sanctions imposed on Russia. (Logo:...

2014-09-11 23:06:23

Leader in Ion Channel Research to have a prominent presence at SPS with particular focus on the Investigational New Drug (IND) application process. Cleveland, Ohio (PRWEB) September 11, 2014 ChanTest will host a sponsored session entitled “The ABC’s of IND’s” at the Safety Pharmacology Society (SPS) Annual Meeting on Monday, October 20th. This session will touch on the shortcomings of the current nonclinical and clinical assays used for cardiac risk assessment, and address some...

2014-09-09 08:31:03

Technology promises to improve recruitment and retention, and bring drugs to market faster NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Two of the most significant challenges in managing a successful clinical trial are recruiting the right test subjects and retaining them for the length of a trial. Time requirements, distance from the study site, number of site visits expected, and transportation concerns make it difficult to recruit patients for trials and contribute to high dropout rates,...

2014-09-08 12:29:15

Now that Childhood Rare Disease Drugs are Profitable, They Might Get Them WASHINGTON, Sept. 8, 2014 /PRNewswire-USNewswire/ -- As we mark the fourth annual observance of National Childhood Cancer Awareness Month, Kids v Cancer celebrates recent achievements in pediatric drug development. The greatest hurdle in battling childhood cancer and rare diseases has long since been the lack of treatments developed specifically for children. Most sick children are left with pass-me-down...

2014-09-08 08:29:26

--Phase 2a Trial is First to Use Crowdsourcing for Protocol Design and Telemonitoring for Patient Data Collection-- NEW YORK, Sept. 8, 2014 /PRNewswire/ -- Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related